Hemodialysis

Hemodialysis
Name	Hemodialysis

Hemodialysis is a renal replacement therapy used to treat advanced Chronic kidney disease and acute Renal failure by removing waste products and excess fluid from the blood. It is provided in outpatient clinics, hospitals, and home settings and intersects with medical specialties, regulatory bodies, and prominent institutions involved in nephrology practice and research. The procedure relies on multidisciplinary teams and technologies developed through collaboration among clinicians, engineers, and policy-makers.

Medical indications

Patients are referred for treatment when uremia, refractory fluid overload, severe electrolyte disturbances, or metabolic acidosis occur in the context of end-stage renal disease from causes such as Diabetic nephropathy, Hypertensive heart disease, Glomerulonephritis, and inherited disorders like Autosomal dominant polycystic kidney disease. Indications also include toxin removal in certain Drug overdose cases and support during acute kidney injury associated with events such as Sepsis, Cardiac surgery, or Rhabdomyolysis. Decision-making involves nephrologists, intensivists, and multidisciplinary teams at centers like Mayo Clinic, Cleveland Clinic, and national agencies such as the National Kidney Foundation and US Food and Drug Administration.

Vascular access

Establishing reliable vascular access is central, typically via arteriovenous fistulas, grafts, or central venous catheters created by vascular surgeons, interventional radiologists, and nephrologists at hospitals including Johns Hopkins Hospital and Massachusetts General Hospital. The preferred permanent access is an autologous arteriovenous fistula fashioned in operating theatres used by teams affiliated with institutions like Stanford Health Care and Mount Sinai Health System. Prosthetic arteriovenous grafts and tunneled central venous catheters are alternatives placed under guidance from specialists trained in techniques pioneered at centers like Karolinska University Hospital and Hôpital Necker. Management of access complications often involves collaboration with vascular research groups and professional societies such as the American Society of Nephrology and European Renal Association.

Hemodialysis procedure and technology

The procedure employs extracorporeal circuits, dialysis machines, and semipermeable membranes developed by biomedical engineers and companies with links to research at universities like Massachusetts Institute of Technology, University of Cambridge, and ETH Zurich. Blood is pumped through tubing and a dialyzer while dialysate flows counter-currently to facilitate diffusion and ultrafiltration; monitoring and machine safety standards are overseen by regulatory agencies including the European Medicines Agency and World Health Organization technical groups. Advances in membrane chemistry, sensors, and software have roots in collaborations with laboratories at Imperial College London, Harvard Medical School, and industry partners such as firms founded in Silicon Valley and Basel. Modalities include high-flux dialysis, hemodiafiltration, and portable or home machines championed by innovators linked to NHS England pilot programs and nonprofit organizations like World Kidney Day initiatives.

Complications and risks

Complications range from intradialytic hypotension and cramping to infections of access sites, bleeding, and dialysis-related amyloidosis; management protocols reflect guidelines from bodies like the Centers for Disease Control and Prevention and the Joint Commission. Cardiovascular morbidity, accelerated atherosclerosis, and arrhythmias are common and are addressed by collaboration between nephrology and cardiology services at tertiary centers such as Mount Sinai Hospital and specialty clinics associated with the American Heart Association. Bloodborne pathogen transmission prevention draws on policies shaped by the Centers for Disease Control and Prevention and infection control research from institutions like Johns Hopkins Bloomberg School of Public Health. Psychosocial burdens, quality-of-life concerns, and access inequities engage advocacy groups including Renal Support Network and policy forums at bodies like the World Health Assembly.

Outcomes and prognosis

Survival and quality-of-life outcomes depend on comorbidities, dialysis adequacy, and access to multidisciplinary care provided by networks involving transplant programs at centers like Baylor College of Medicine and University of California, San Francisco Medical Center. Comparative studies and registries maintained by organizations such as the United States Renal Data System and the European Renal Association–European Dialysis and Transplant Association inform prognostic models used by clinicians and health systems including Veterans Health Administration clinics. Long-term outcomes are influenced by vascular access longevity, cardiovascular events, and opportunities for kidney transplantation through programs coordinated with transplant centers and agencies like Organ Procurement and Transplantation Network.

History and development

The evolution of the therapy traces through milestones involving researchers and clinicians affiliated with institutions such as Karolinska Institutet, UCLA Medical Center, and University of Washington Medical Center and owes to technological, surgical, and physiological advances. Early membrane and extracorporeal circulation experiments intersected with work from laboratories at University of Toronto, contributions from inventors and physicians recognized by awards like the Lasker Award, and developments in dialysis machine manufacturing in industrial centers including Zurich and New York City. International collaboration, wartime medicine adaptations, and postwar public health policy shaped dissemination through networks tied to organizations like the Red Cross, ministries of health of countries such as Sweden and United Kingdom, and global research consortia that include universities across North America, Europe, and Asia.

Category:Nephrology